CAR-Ts’ place in lymphoma therapy uncertain given well-served treatment landscape, high cost – experts

12 Apr 2016

Chimeric antigen receptor T-cell (CAR-T) therapies have drawn expert uncertainty about their potential place in non-Hodgkin's lymphoma (NHL) treatment. They pointed to factors like a highly competitive market, cost concerns and infrastructure requirements.

Given that response rates in many NHL histologies have been much lower than the complete response (CR) rates of often 80% or more seen in acute lymphoblastic leukemia (ALL), some experts added it would be important to find biomarkers to better predict which NHL patients might respond and thus increase response rates.

In terms of CAR-T development targeted at NHL, Juno Therapeutics (NASDAQ:JUNO) plans to launch a registration-directed study of JCAR017 in NHL in 1Q17, according to an analyst note. Kite Pharma (NASDAQ:KITE) presented updated results from the Phase I ZUMA-1 study (NCT02348216) of KTE-C19 at the American Association of Cancer Research's annual meeting in 16-20 April. Novartis (VTX:NOVN) presented CTL019 Phase IIa data in the NHL subtypes diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL) at the American Society of Hematology's (ASH's) 2015 annual conference in December.

Already a subscriber? Login to read the full article.